Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
2009 NOV 28 ... in direct costs incurred in connection with the clinical development of FV-100 and the preclinical development of INX-189, offset in part by a $0.1 million decrease in other non-direct ... on INX-189 in a poster at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. A copy of the poster presentation is available ...
2009 NOV 25 ... for the quarter was due primarily to decreased spending in Neurogen's clinical and preclinical drug development programs as well as the 2008 and 2009 restructuring of the Company's ... The Company also announced its analysis of results from a previously suspended Phase 2 study of aplindore in Restless Legs Syndrome (RLS) and that it has entered into an agreement ...
2009 NOV 23 ... and similar approaches may be very helpful in evaluating drug-induced organ damage in preclinical animal models," wrote H. Mischak and colleagues. The researchers ... the urinary proteome of patients suffering from tubular injury (Fanconi syndrome). Our study strongly suggests that (drug-induced) nephrotoxicity can be detected with high accuracy ...
2009 NOV 23 ... may prevent and induce regression of prostate cancer and other malignancies in preclinical models, but the mechanisms that may explain these effects are not fully defined." ... agent's effects in prostate cancer." Gibbs and colleagues published their study in Proceedings of the National Academy of Sciences of the United States of America ...
2009 NOV 23 ... model for HCV infection would significantly expedite antiviral compound development and preclinical testing, as well as open new avenues to decipher the mechanisms that underlie viral ... biology," wrote A. Ploss and colleagues, Rockefeller University, Center for the Study of Hepatitis C. The researchers concluded: "We highlight three ...
2009 NOV 23 ... changes signifying Alzheimer disease is difficult. To model the cognitive decline in preclinical Alzheimer disease," scientists in the United States report. "Longitudinal ... disease," scientists in the United States report. "Longitudinal archival study comparing individuals who became demented during follow-up and people who remained ...
2009 NOV 23 ... intradermally or in window chamber preparations in BALB/c nu/nu mice were used as preclinical tumor models. Radiation dose resulting in 50% local tumor control was higher by a factor ... fluid pressure in human tumor xenografts,' is the subject of a report. According to a study from Oslo, Norway, "Interstitial fluid pressure (IFP) has been shown to be an ...
2009 NOV 23 ... According to recent research from the United States, "Preclinical and clinical research findings have revealed that the hormone progesterone, when acutely ... cerebral edema after TBI." Macnevin and colleagues published their study in the Journal of Medicinal Chemistry (Development and Screening of Water-Soluble ...
2009 NOV 23 ... is largely responsible for the high mortality observed in chronic kidney disease (CKD). Preclinical studies have evidenced an association between serum levels of indoxyl sulfate (IS, a ... a protein-bound uremic toxin) and vascular alterations." "The aim of this study is to investigate the association between serum IS, vascular calcification, vascular ...
2009 NOV 23 ... inhibits primary tumor growth and the incidence of lymphatic and pulmonary metastases in preclinical animal models. Here, the efficacy of sequential treatment with paclitaxel and alpha-TEA ... Exp Biol Med 234:1244-1252, 2009." Latimer and colleagues published their study in Experimental Biology and Medicine (Aerosol Delivery of Liposomal Formulated ...
2009 NOV 23 ... than in isolation, would allow more effective and efficient measures of tumor growth in preclinical studies. Herein we describe combining BLI and MRI studies to characterize tumor growth ... in preclinical therapeutic studies." Jost and colleagues published their study in Molecular Imaging (Measuring Brain Tumor Growth: Combined Bioluminescence ...
2009 NOV 28 ... research team from Cincinnati Children's Hospital Medical Center reports its preclinical laboratory results this week in the early edition of Proceedings of the National Academy ... in the early edition of Proceedings of the National Academy of Sciences.The study suggests a new approach to molecular gene therapy and a much-needed improved treatment ...
Subject: Cincinnati Children's Hospital Medical Center
2009 NOV 23 ... The researchers concluded: "Finally, the method was successfully applied to a preclinical pharmacokinetic study of armillarisin A in four rats following an intravenous ...
2009 NOV 25 ... reconstructions were successful, allowing the release of the new plates and software for preclinical studies in mice."Vunckx and colleagues published their study in IEEE ...
2009 NOV 23 ... of this nanomedicine for clinical trials, in this communication we have tested the preclinical efficacy of squalenoyl gemcitabine nanomedicine on several human tumor cell lines and on ... to that of gemcitabine free." Reddy and colleagues published their study in Molecular Pharmaceutics (Anticancer Efficacy of Squalenoyl Gemcitabine Nanomedicine ...
2009 NOV 23 ... delivers a three-pronged attack on CRPC cells, and has shown very promising results in preclinical models of prostate cancer," said Seth Harrison, M.D., chairman and acting chief ... with TOK-001 in patients with CRPC. The Phase 1 component of the trial is a dose-finding study to evaluate escalating dose levels of TOK-001 and is expected to enroll nine patients. ...
2009 NOV 23 ... trial of TRU-016 for the treatment of chronic lymphocytic leukemia (CLL), and 2) a preclinical study demonstrating the effect of Trubion's Tru-ADhanCe™ technology in promoting ...
2009 NOV 23 ... from our Phase 1 study of VTP-27999, which was initiated in September, as well as select preclinical findings." Windhover's Therapeutic Area Partnerships meeting is the ...
2009 NOV 23 ... arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less ... or metastatic soft tissue sarcoma. As previously announced, having achieved the study-specified efficacy milestone following planned safety and efficacy review by the Data ...
2009 NOV 23 ... arsenic being developed for the treatment of various hematologic and solid cancers. Preclinical and clinical studies to date have demonstrated that darinaparsin is considerably less ... randomized Phase II trial in metastatic or unresectable soft tissue sarcoma achieved the study-specified efficacy milestone following planned safety and efficacy review by the Data ...
